Suggestions
Jennifer Steger
Pharmacology PhD - Co-Founder + Chief Scientific Officer at Nanodropper, Inc. - Forbes 30 Under 30 2021
Professional Background
Jennifer Steger is a distinguished scientist and innovator in the field of neuroscience and pharmacology. With an exceptional educational background highlighted by a Bachelor of Science in Neuroscience from the esteemed Brown University coupled with a Doctor of Philosophy in Pharmacology from the renowned University of Washington, Jennifer has honed her expertise to focus on both basic and translational research in neuroscience and pharmacology.
Currently, she serves as the Co-Founder and Chief Scientific Officer at Nanodropper, Inc., where she plays a pivotal role in revolutionizing drug delivery systems, enhancing access to medications, and improving patient outcomes through innovative technologies. Her leadership is marked by a commitment to scientific excellence and a passion for advancing healthcare solutions that leverage her deep understanding of drug mechanisms and brain functions.
Prior to her pivotal role at Nanodropper, Inc., Jennifer's career in academia was characterized by a series of substantial research positions that underscored her dedication to scientific inquiry. She was a Neuropharmacology Ph.D. student at the University of Washington, where she delved into the intricacies of drug interactions within the nervous system. Her foundational research skills were developed during her time as a Research Assistant at the prestigious Beth Israel Deaconess Medical Center and Harvard Medical School, where she contributed to cutting-edge research projects that aimed to understand complex neurological disorders.
Education and Achievements
Jennifer's academic journey began at Brown University, where she pursued her Bachelor's degree in Neuroscience with Honors. This formative experience provided her with a robust understanding of the principles of neuroscience, setting the stage for her advanced studies. Her commitment to her field is reflected in her choice to further her education at the University of Washington, where she earned a Ph.D. in Pharmacology.
Throughout her academic career, Jennifer has been recognized for her dedication to research excellence and her innovative approach to problem-solving. Her honors research at Brown not only enhanced her analytical and scientific writing skills but also deepened her understanding of the neurological mechanisms at play in various disorders, making her insights invaluable in clinical settings.
In addition to her work at major institutions, Jennifer has demonstrated her adaptability and resourcefulness as a Summer Research Student at The Juneau Icefield Research Program (JIRP), where she combined her passion for research with the beauty of the Alaskan landscape, contributing to environmental science while cultivating her love for interdisciplinary studies. Her time at UC Berkeley as a Research Assistant further solidified her research acumen, as she engaged in diverse projects aimed at unraveling the complexities of drug effects on the brain.
Achievements
Jennifer Steger's career is marked by numerous significant accomplishments that reflect her dedication to advancing neuroscience and pharmacology. As a Co-Founder and Chief Scientific Officer at Nanodropper, Inc., her visionary leadership has been instrumental in harnessing new technologies to improve drug delivery systems. This role not only allows her to apply her scientific knowledge directly to industry but also showcases her ability to translate complex scientific concepts into practical applications that benefit patients.
Her strong academic foundation, supported by rigorous training and collaborative research experiences, has equipped her to make meaningful contributions to the scientific community. With a breadth of experience across prestigious institutions, Jennifer's ability to work collaboratively with multidisciplinary teams sets her apart as a leader in her field.
In summary, Jennifer Steger embodies the spirit of innovation and dedication to science that drives the field of pharmacology. Her impressive educational background, combined with her entrepreneurial efforts at Nanodropper, Inc., positions her as a thought leader in the development of new therapeutic approaches that promise to enhance treatment availability and effectiveness for various neurological conditions. The impact of her work will undoubtedly contribute to the future of medicine, as she continues to bridge the gap between research and real-world applications.